Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Viruses
2.3. Number of ADV, HSV-1/2, EBV, CMV, BKV and JCV Virus Copies in Renal Tumor Tissue
2.4. Number of EBV and ADV Virus Copies in Plasma
2.5. Calculation of Viral Load
- human adenovirus (ADV): 500, 5000, 50,000, 500,000 cp/mL,
- herpes simplex virus-1 (HSV-1): 2, 20, 200, 2000 cp/µL,
- herpes simplex virus-2 (HSV-2): 2, 20, 200, 2000 cp/µL,
- Epstein-Barr virus (EBV): 10, 100, 1000, 10,000 cp/µL,
- cytomegalovirus (CMV): 10, 100, 1000, 10,000 cp/µL,
- BK virus (BKV): 10, 100, 1000, 10,000 cp/µL,
- John Cunningham virus (JCV): 10, 100, 1000, 10,000 cp/µL.
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016, 70, 93–105. [Google Scholar] [CrossRef] [PubMed]
- Hidayat, K.; Du, X.; Zou, S.Y.; Shi, B.M. Blood pressure and kidney cancer risk: Meta-analysis of prospective studies. J. Hypertens. 2017, 35, 1333–1344. [Google Scholar] [CrossRef] [PubMed]
- Cumberbatch, M.G.; Rota, M.; Catto, J.W.; La Vecchia, C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur. Urol. 2016, 70, 458–466. [Google Scholar] [CrossRef] [Green Version]
- Gild, P.; Ehdaie, B.; Kluth, L.A. Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival. Curr. Opin. Urol. 2017, 27, 409–414. [Google Scholar] [CrossRef]
- Huang, K.L.; Mashl, R.J.; Wu, Y.; Ritter, D.I.; Wang, J.; Oh, C.; Paczkowska, M.; Reynolds, S.; Wyczalkowski, M.A.; Oak, N.; et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 2018, 173, 355–370. [Google Scholar] [CrossRef] [Green Version]
- Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 2014, 32, 1968–1976. [Google Scholar] [CrossRef] [Green Version]
- Pisani, P.; Parkin, D.M.; Muñoz, N.; Ferlay, J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomark. Prev. 1997, 6, 387–400. [Google Scholar]
- Alibek, K.; Karatayeva, N.; Bekniyazov, I. The role of infectious agents in urogenital cancers. Infect. Agent Cancer 2012, 7, 35. [Google Scholar] [CrossRef] [Green Version]
- Cai, T.; Di Vico, T.; Durante, J.; Tognarelli, A.; Bartoletti, R. Human papilloma virus and genitourinary cancers: A narrative review. Minerva Urol. Nefrol. 2018, 70, 579–587. [Google Scholar] [CrossRef]
- Li, N.; Yang, L.; Zhang, Y.; Zhao, P.; Zheng, T.; Dai, M. Human papillomavirus infection and bladder cancer risk: A meta-analysis. J. Infect. Dis. 2011, 204, 217–223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jørgensen, K.R.; Jensen, J.B. Human papillomavirus and urinary bladder cancer revisited. APMIS 2020, 128, 72–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shen, C.H.; Wu, J.D.; Hsu, C.D.; Jou, Y.; Lin, C.; Wang, M.; Wu, S.; Chan, M.W.Y.; Chiang, M.; Fang, C.; et al. The high incidence of JC virus infection in urothelial carcinoma tissue in Taiwan. J. Med. Virol. 2011, 83, 2191–2199. [Google Scholar] [CrossRef]
- Geetha, D.; Tong, B.C.; Racusen, L.; Markowitz, J.S.; Westra, W.H. Bladder carcinoma in a transplant recipient: Evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002, 73, 1933–1936. [Google Scholar] [CrossRef] [PubMed]
- Zapatka, M.; Borozan, I.; Brewer, D.S.; Murat Iskar, A.G.; Iskar, M.; Grundhoff, A.; Alawi, M.; Desai, N.; Sültmann, H.; Moch, H.; et al. The landscape of viral associations in human cancers. Nat. Genet. 2020, 52, 320–330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yin, B.; Liu, W.; Yu, P.; Liu, C.; Chen, Y.; Duan, X.; Liao, Z.; Chen, Y.; Wang, X.; Pan, X.; et al. Association between human papillomavirus and prostate cancer: A meta-analysis. Oncol. Lett. 2017, 14, 1855–1865. [Google Scholar] [CrossRef]
- Russo, G.I.; Calogero, A.E.; Condorelli, R.A.; Scalia, G.; Morgia, G.; La Vignera, S. Human papillomavirus and risk of prostate cancer: A systematic review and meta-analysis. Aging Male 2020, 23, 132–138. [Google Scholar] [CrossRef] [PubMed]
- Garolla, A.; Vitagliano, A.; Muscianisi, F.; Valente, U.; Ghezzi, M.; Andrisani, A.; Ambrosini, G.; Foresta, C. Role of Viral Infections in Testicular Cancer Etiology: Evidence from a Systematic Review and Meta-Analysis. Front. Endocrinol. 2019, 10, 355. [Google Scholar] [CrossRef]
- Strickler, H.D.; Schiffman, M.H.; Shah, K.V.; Rabkin, C.S.; Schiller, J.T.; Wacholder, S.; Clayman, B.; Viscidi, R.P. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer Prev. 1998, 7, 305–313. [Google Scholar] [CrossRef]
- Kim, K.H.; Han, E.M.; Lee, E.S.; Park, H.S.; Kim, I.; Kim, Y.S. Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues. BJU Int. 2005, 96, 547–552. [Google Scholar] [CrossRef]
- Shimakage, M.; Kawahara, K.; Harada, S.; Sasagawa, T.; Shinka, T.; Oka, T. Expression of Epstein-Barr virus in renal cell carcinoma. Oncol. Rep. 2007, 18, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Salehipoor, M.; Khezri, A.; Behzad-Behbahani, A.; Geramizadeh, B.; Rahsaz, M.; Aghdaei, M.; Afrasiabi, M.A. Role of viruses in renal cell carcinoma. Saudi J. Kidney Dis. Transpl. 2012, 23, 53–57. [Google Scholar] [PubMed]
- Heim, A.; Ebnet, C.; Harste, G.; Pring-Akerblom, P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 2003, 70, 228–239. [Google Scholar] [CrossRef] [PubMed]
- Lion, T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin. Microbiol. Rev. 2014, 27, 441–462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matthes-Martin, S.; Feuchtinger, T.; Shaw, P.J.; Engelhard, D.; Hirsch, H.H.; Cordonnier, C.; Ljungman, P. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011). Transpl. Infect. Dis. 2012, 14, 555–563. [Google Scholar] [CrossRef] [PubMed]
- Florescu, D.F.; Stohs, E.J. Approach to infection and disease due to adenoviruses in solid organ transplantation. Curr. Opin. Infect. Dis. 2019, 32, 300–306. [Google Scholar] [CrossRef] [PubMed]
- Watcharananan, S.P.; Avery, R.; Ingsathit, A.; Malathum, K.; Chantratita, W.; Mavichak, V.; Chalermsanyakorn, P.; Jirasiritham, S.; Sumethkul, V. Adenovirus disease after kidney transplantation: Course of infection and outcome in relation to blood viral load and immune recovery. Am. J. Transplant. 2011, 11, 1308–1314. [Google Scholar] [CrossRef]
- Yao, Q.Y.; Rickinson, A.B.; Epstein, M.A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer 1985, 35, 35–42. [Google Scholar] [CrossRef]
- Kanda, T.; Yajima, M.; Ikuta, K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 2019, 110, 1132–1139. [Google Scholar] [CrossRef]
- Feederle, R.; Klinke, O.; Kutikhin, A.; Poirey, R.; Tsai, M.H.; Delecluse, H.J. Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types. Curr. Top. Microbiol. Immunol. 2015, 390, 119–148. [Google Scholar]
- White, R.E.; Rämer, P.C.; Naresh, K.N.; Meixlsperger, S.; Pinaud, L.; Rooney, C.; Savoldo, B.; Coutinho, R.; Bödör, C.; Gribben, J.; et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Investig. 2012, 122, 1487–1502. [Google Scholar] [CrossRef] [PubMed]
- Kelly, G.L.; Milner, A.E.; Baldwin, G.S.; Bell, A.I.; Rickinson, A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 2006, 103, 14935–14940. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lo, A.K.; Dawson, C.W.; Jin, D.Y.; Lo, K.W. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J. Pathol. 2012, 227, 392–403. [Google Scholar] [CrossRef] [PubMed]
- Murray, P.G.; Young, L.S. Epstein-Barr virus infection: Basis of malignancy and potential for therapy. Expert. Rev. Mol. Med. 2001, 3, 1–20. [Google Scholar] [CrossRef]
- Fukayama, M.; Hayashi, Y.; Iwasaki, Y.; Chong, J.; Ooba, T.; Takizawa, T.; Koike, M.; Mizutani, S.; Miyaki, M.; Hirai, K. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab. Investig. 1994, 71, 73–81. [Google Scholar]
- Murphy, G.; Pfeiffer, R.; Camargo, M.C.; Rabkin, C.S. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location [published correction appears in Gastroenterology. 2011 Mar;140(3):1109]. Gastroenterology 2009, 137, 824–833. [Google Scholar] [CrossRef] [Green Version]
- Camargo, M.C.; Kim, W.H.; Chiaravalli, A.M.; Kim, K.; Corvalan, A.H.; Matsuo, K.; Yu, J.; Sung, J.J.Y.; Herrera-Goepfert, R.; Meneses-Gonzalez, F.; et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis. Gut 2014, 63, 236–243. [Google Scholar] [CrossRef]
- Törnell, J.; Farzad, S.; Espander-Jansson, A.; Matejka, G.; Isaksson, O.; Rymo, L. Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Oncogene 1996, 12, 1521–1528. [Google Scholar]
- Karaarslan, S.; Şen, N. Investigation of the relationship of Epstein-Barr virus with in situ hybridization in renal-cell carcinomas. Ann. Diagn. Pathol. 2018, 34, 45–49. [Google Scholar] [CrossRef]
- Kang, M.J.; Kim, K.M.; Bae, J.S.; Park, H.S.; Lee, H.; Chung, M.J.; Moon, W.S.; Lee, D.G.; Jang, K.Y. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl. Oncol. 2013, 6, 282–289. [Google Scholar] [CrossRef] [Green Version]
- Becker, J.L.; Miller, F.; Nuovo, G.J.; Josepovitz, C.; Schubach, W.H.; Nord, E.P. Epstein-Barr virus infection of renal proximal tubule cells: Possible role in chronic interstitial nephritis. J. Clin. Investig. 1999, 104, 1673–1681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zisman, A.; Pantuck, A.J.; Dorey, F.; Chao, D.H.; Gitlitz, B.J.; Moldawer, N.; Lazarovici, D.; deKernion, J.B.; Figlin, R.A.; Belldegrun, A.S. Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 2002, 20, 1368–1374. [Google Scholar] [CrossRef] [PubMed]
- Frank, I.; Blute, M.L.; Cheville, J.C.; Lohse, C.M.; Weaver, A.L.; Zincke, H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J. Urol. 2002, 168, 2395–2400. [Google Scholar] [CrossRef]
- Blazquez-Navarro, A.; Dang-Heine, C.; Wittenbrink, N.; Bauer, C.; Wolk, K.; Sabat, R.; Westhoff, T.H.; Sawitzki, B.; Reinke, P.; Thomusch, O.; et al. BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study. EBioMedicine 2018, 34, 113–121. [Google Scholar] [CrossRef] [Green Version]
- Wijarnpreecha, K.; Nissaisorakarn, P.; Sornprom, S.; Thongprayoon, C.; Thamcharoen, N.; Maneenil, K.; Podboy, A.J.; Cheungpasitporn, W. Hepatitis C infection and renal cell carcinoma: A systematic review and meta-analysis. World J. Gastrointest. Pathophysiol. 2016, 7, 314–319. [Google Scholar] [CrossRef] [PubMed]
Total Number of Positive Cases | Mean Value of the Viral Copy Numbers/uL | |
---|---|---|
EBV | 8 | 198.3 (range 29–829) |
ADV | 3 | 619.7 (range 393–867) |
HSV-1 | 0 | - |
HSV-2 | 0 | - |
CMV | 0 | - |
BKV | 0 | - |
JCV | 0 | - |
Parameter | Non-Infected Patients (Controls) (n = 17) | Infected Patients (ADV or/and EBV Infection) (n = 10) | p-Value (Controls vs. ADV/EBV) | Patients with ADV Infection (n = 3) | p-Value (ADV Positive vs. ADV Negative Patients) | Patients with EBV Infection (n = 8) | p-Value (EBV Positive vs. EBV Negative Patients) |
---|---|---|---|---|---|---|---|
Percentage of women | 41.2% | 30.0% | >0.05 | 66.7% | >0.05 | 25.0% | >0.05 |
Mean age (years) | 57.6 | 71.3 | 0.02 | 73.3 | >0.05 | 69.9 | >0.05 |
Mean BMI (kg/m2) | 24.5 | 27.9 | 0.01 | 26.7 | >0.05 | 28.3 | 0.01 |
Percentage of overweight patients (BMI > 25 kg/m2) | 41.2% | 80.0% | 0.0499 | 66.7% | >0.05 | 87.5% | 0.03 |
Percentage of patients with diabetes | 11.8% | 50.0% | 0.02 | 33.3% | >0.05 | 62.5% | 0.006 |
Percentage of patients with uncontrolled dyslipidemia | 41.2% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |
Median white blood cell count (k/uL) | 8.79 | 6.14 | >0.05 | 10.04 | >0.05 | 5.97 | 0.049 |
Median hemoglobin concentration (g/dL) | 13.8 | 13.1 | >0.05 | 13.3 | >0.05 | 13.1 | >0.05 |
Percentage of abnormal CRP values (>5 mg/L) | 23.5% | 30.0% | >0.05 | 66.7% | >0.05 | 12.5% | >0.05 |
Median creatinine serum concentration (mg/dL) | 0.76 | 1.09 | 0.047 | 1.11 | >0.05 | 1.08 | >0.05 |
Percentage of patients with chronic kidney disease (GFR < 60 mL/min/1.73 m2) | 29.4% | 70.0% | 0.04 | 100% | 0.04 | 62.5% | >0.05 |
Percentage of patients with proteinuria (>30 mg/dL) | 23.5% | 20.0% | >0.05 | 33.3% | >0.05 | 12.5% | >0.05 |
Percentage of patients with hematuria (>3 erythrocytes/HPF) | 41.2% | 50.0% | >0.05 | 66.7% | >0.05 | 50.0% | >0.05 |
Percentage of patients with pyuria (>5 leukocytes/HPF) | 35.3% | 50.0% | >0.05 | 66.7% | >0.05 | 37.5% | >0.05 |
Pathological stage of cancer | pT1a–58.8% pT1b–23.5% pT2a–5.9% pT2b–5.9% pT3a–5.9% pT3b-4–0% missing–0% | pT1a–20% pT1b–20% pT2a–20% pT2b–10% pT3a–20% pT3b-4–0% missing–10% | >0.05 | pT1a–0% pT1b–33.3% pT2a–33.3% pT2b–33.3% pT3a–0% pT3b-4–0% missing–0% | >0.05 | pT1a–25.0% pT1b–12.5% pT2a–12.5% pT2b–12.5% pT3a–25.0% pT3b-4–0% missing–12.5% | >0.05 |
Histological grade of cancer | low grade–76.5% high grade–11.8% missing–11.8% | low grade–40.0% high grade–60.0% missing–0% | 0.01 | low grade–33.3% high grade–66.7% | >0.05 | low grade–37.5% high grade–62.5% | 0.02 |
Histological RCC subtype | clear cell–76.5% papillary–5.9% chromophobe–17.6% other–0% | clear cell–40.0% papillary–50.0% chromophobe–0% other–10.0% | 0.004 | clear cell–33.3% papillary–66.7% chromophobe–0% other–0% | >0.05 | clear cell–50.0% papillary–37.5% chromophobe–0% other–12.5% | >0.05 |
Surgical procedure | partial nephrectomy–47.1% radical nephrectomy–52.9% | partial nephrectomy–40.0% radical nephrectomy–60.0% | >0.05 | partial nephrectomy–33.3% radical nephrectomy–66.7% | >0.05 | partial nephrectomy–37.5% radical nephrectomy–62.5% | >0.05 |
12-month cancer recurrence rate | 12.5% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kryst, P.; Poletajew, S.; Wyczałkowska-Tomasik, A.; Gonczar, S.; Wysocki, M.; Kapuścińska, R.; Krajewski, W.; Zgliczyński, W.; Pączek, L. Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. J. Clin. Med. 2020, 9, 3195. https://doi.org/10.3390/jcm9103195
Kryst P, Poletajew S, Wyczałkowska-Tomasik A, Gonczar S, Wysocki M, Kapuścińska R, Krajewski W, Zgliczyński W, Pączek L. Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. Journal of Clinical Medicine. 2020; 9(10):3195. https://doi.org/10.3390/jcm9103195
Chicago/Turabian StyleKryst, Piotr, Sławomir Poletajew, Aleksandra Wyczałkowska-Tomasik, Stefan Gonczar, Maciej Wysocki, Renata Kapuścińska, Wojciech Krajewski, Wojciech Zgliczyński, and Leszek Pączek. 2020. "Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy" Journal of Clinical Medicine 9, no. 10: 3195. https://doi.org/10.3390/jcm9103195
APA StyleKryst, P., Poletajew, S., Wyczałkowska-Tomasik, A., Gonczar, S., Wysocki, M., Kapuścińska, R., Krajewski, W., Zgliczyński, W., & Pączek, L. (2020). Epstein-Barr Virus and Human Adenovirus Viremia in Renal Tumors Is Associated with Histological Features of Malignancy. Journal of Clinical Medicine, 9(10), 3195. https://doi.org/10.3390/jcm9103195